-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2655 The Efficacy and Safely of Anticoagulation for the Management of Gonadal Vein Thrombosis

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Anticoagulant Drugs, Research, Non-Biological therapies, Clinical Research, Therapies
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Cameron Brown1*, Sarah Ng, MD2,3*, Farah Zarka, MD4*, Aurélien Delluc, MD, PhD5,6* and Marc Carrier, MD5,6

1Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada
2University Of South Wales, Sydney, Australia
3Department of Haematology, Liverpool Hospital, Sydney, Australia
4Department of Medicine, Ottawa Hosptial Research Institute, Ottawa, ON, Canada
5Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
6Department of Medicine, The Ottawa Hospital and the University of Ottawa, Ottawa, ON, Canada


Gonadal vein thrombosis (GVT) is an uncommon condition that has been associated with different risk factors (e.g., post-partum period, cancer, recent pelvic surgery, etc.). The optimal management of GVT remains unclear. Anticoagulation therapy may help to mitigate the risk of thrombosis extension and recurrent venous thromboembolism (VTE) but may also be associated with bleeding complications. We sought to assess the efficacy and safety of anticoagulation therapy in patients with GVT.


A systematic search of MEDLINE, EMBASE and PubMed for randomized controlled trials and observational studies was performed. Studies with patients presenting with GVT defined as ovarian vein thrombosis or testicular vein thrombosis and reporting at least one of the desired outcomes were included in the analysis.The primary efficacy outcome was recurrent VTE, and the primary safety outcome was major bleeding episode. Secondary outcomes included clinically relevant non-major bleeding and overall mortality. Incidence rates of the outcomes were pooled using the random effects model and expressed as event per 100 patient-years with its associated 95% confidence intervals (CI) using R software.


The search strategy identified 7084 article records. A total of 13 observational studies (1039 patients) with GVT met the inclusion criteria and were included in the analysis. Only one study reported the incidence of testicular vein thrombosis. Hence, 96% of the total patient population were females with ovarian vein thrombosis. Overall, the incidence rate per 100 patient-years for recurrent VTE was 3.60 (95% CI: 2.12-6.13; I-square 75%; Figure 1). A large majority of studies did not report if recurrent events occurred during or following discontinuation of anticoagulation. Similarly, most studies did not report on major or clinically relevant non-major bleeding events, or overall mortality preventing the possibility of conducting pooled analyses for these outcomes.


GVT seems to be associated with a relatively low risk of recurrent VTE. However, it remains unclear if anticoagulant therapy is associated with a favorable risk/benefit ratio. Future studies (e.g., registries, population-based studies) are needed to investigate the efficacy of anticoagulant and whether it outweighs the risk of bleeding in this patient population.

Disclosures: Delluc: BMS-Pfizer: Honoraria, Other: Payments made to my institution; LeoPharma: Honoraria, Other: Payments made to my institution. Carrier: BMS-Pfizer: Honoraria, Research Funding; Bayer: Honoraria; Leo Pharma: Honoraria, Research Funding; Sanofi: Honoraria, Other: Payments made to my institution; Servier: Honoraria, Other: Payments made to my institution; Anthos: Honoraria, Other: Payments made to my institution.

*signifies non-member of ASH